Healthcare – The CEO Magazine – India The CEO Magazine: Best Monthly Business Magazine for Business Leaders and Decision Makers Mon, 10 Aug 2020 13:24:04 +0000 en-US hourly 1 Healthcare – The CEO Magazine – India 32 32 From Safety Footwear Export to India’s Most Promising PPE Brand Wed, 10 Jun 2020 13:20:48 +0000 From Safety Footwear Export to India’s Most Promising PPE Brand Varun Budhiraja’s Next  Plan? Personalising Protection down to its basic elements. Incorporated in 2004, Euro Safety Footwear has for 15 years now; led in the P.P.E. and industrial safety footwear manufacturing vertical. The company has held its position steadily, to-date remaining one of Asia’s largest; […]]]>

From Safety Footwear Export to India’s Most Promising PPE Brand

Varun Budhiraja’s Next  Plan?

Personalising Protection down to its basic elements.

Incorporated in 2004, Euro Safety Footwear has for 15 years now; led in the P.P.E. and industrial safety footwear manufacturing vertical. The company has held its position steadily, to-date remaining one of Asia’s largest; and leading integrated manufacturers of PPE (Personal Protective Equipment). 

Under the wise leadership of Varun Budhiraja, Director, Euro Safety Group of Companies, they launched operations across India. He successfully introduced the first brand ‘Euro Security’ to the market; for safety footwear in India, Nepal, Bhutan, and the Middle East. And subsequently added products for global markets by establishing strategic manufacturing alliances in China, Sri Lanka, & Malaysia. After Varun sensed the potential in SAARC & MENA regions, from 2016; the company steadily started escalating the production competence of their existing footwear manufacturing facility in Agra. In 2019, Euro Safety Equipment (ESE) was established to focus on the manufacture of garments, gloves, and masks. Now they are also eying the hospitality and aviation markets in India.


As the Director of Euro Safety Group of Companies, he started at a young age of 20; after earning a graduation degree from Lancaster University, UK, in Marketing and Entrepreneurship. He also has degrees in footwear designing, digital marketing, luxury management; from Milan, Mannheim and Paris respectively. And holds C-level designations in Roger Group’s allied firms and organizations.

On completion of a stupendous 15 years of successful operations, The CEO Magazine, in an enlightening conversation with the visionary-Director, Varun; found a chance to know more about his lesser-known sides. The company, industry, business model, corporate ethos, work culture, plans, technological bends and more;

TCM: What is your role professionally apart from the one at Euro Safety Group?

Varun: Aside from my role in Euro Safety Group, I also oversee Boa Safety Solutions (owned by the Euro Safety Group) for the distribution of PPE in South Africa. I was instrumental in developing the marketing team, channel partners and product line-up as per the requirements of the South African market.

As if to compliment my work in these manufacturing companies, I am also the marketing director of D’Selva Infotech, an IT-based Service Company. Which is into web and app development, they made both for Euro Safety. At D’Selva Infotech, I contribute with strategizing and solutions development. Lastly, I am also the founder and Vice President of Roger Foundation, the CSR arm of Euro Safety Group; so, quite the whole package, between manufacturing, services, and CSR.

TCM: Apart from work where does your interest incline, tell us more about your passion, interests etc?

Varun: Unbeknownst to most people, I am a published CREATOR/Author of the book “VD Artistic Verses”. I am also actively involved in producing copy for company creative and in strategizing for Euro Safety Group. If I was not in the field of PPE Manufacturing; I would most likely have been part of some creative field like; advertising, copywriting or would have pursued becoming a chef. However, since I have to manage the company as well, I have taken a compromise approach, mixing passion and profession. To balance the two, I live out my passion through my business career of directing the marketing, design and branding team at Euro Safety. A person’s passion and profession need not be mutually exclusive.

TCM: What was the rationale behind choosing the path to this business line?

Varun: Right from the outset, I sensed a lacuna in the Indian PPE market – that India does not have an organize; one-stop shop of PPE for all sectors and industry verticals.

Though we started with only footwear manufacture; we have diversified into a variety of safety equipment. And ultimately aspire to be a go-to-supplier for all PPE needs in India and south Asia.

As you and your readers will know, the chain is only as strong as the weakest link, and unless Indian companies have top quality PPE, our manufacturing will never be able to compete with those of the West and China.

My long term vision and future plan is to make Euro Safety Group; the biggest and most reliable supplier of PPE for all sorts of workers. Who will feel secure in the knowledge that though accidents are inevitable in a hazardous work environment. Such as theirs, the top class PPE of Euro Safety will be with them all the way, to mitigate the risks and damages.

In the coming years, I want to ensure that Euro Safety Group keeps doubling in size every 5 years for decades, consequently ensuring that, thanks to our PPE, employees in emerging markets such as India and South Asia work under utmost standards of psychological safety.

Greater psychological safety is proven by management research to improve both; worker-morale (and thus output) inside the company and brand-image outside. By improving the safety standards of workers, I want to make the Euro Safety Group of the future. A multi-million-dollar enterprise, synonymous with world-class PPE at affordable price points. Euro Safety Group is committed to ensuring that Indian and South Asian companies provide their employees with the best standards of safety equipment and consequently high degrees of psychological safety.

TCM: Tell us about your team. With such a fast-growing team; how do you make sure everybody stays motivated and how do you support the corporate culture?

Varun: We at Euro Safety Group have all sorts of people from engineers to technicians, manufacturers and marketers in our team. We have engaged skilled and experienced technicians who are well versed in operating the latest imported machinery and are aware of all the nuances of manufacturing industrial safety footwear.

While selecting my team, I make sure that their capabilities and qualifications are resonant with the long-term vision; I have for the company. The other thing that I stress on is chemistry between the team members; because their collective output needs to reflect our corporate culture. Each party has their jobs cut out, and I make sure that each is provided with the best; in class equipment and facilities and that they all work synergistically. For Euro Safety Group to go from strength to strength; the whole needs to be more than the sum of its parts.

TCM: How do you think you’re different from your peers/competitors, what makes you different from them?

Varun: Euro Safety Group started as the PPE diversification of Roger Group. Unlike most other players in this industry, we brought many decades of manufacturing experience; reputation, established supply lines and distribution channels from the beginning. As an exporter of quality footwear, we also had 1st world standards quality control in place for a long time. Hence, unlike most of our competitors, we made quality products in the PPE space, right from the outset. And since then, we have been extending our product line; and customizing our product offering to suit the specific demands of the industry verticals we supply to.

In future we are also planning to have an investment arm – suppose some bio-tech student in some Indian institute, develops a polymer, that could be used to make better and/or cheaper safety equipment, we will be happy to incubate his or her research.

Just like Indian companies must embrace better safety standards to remain competitive; so must our manufacturers embrace better and newer technology, to truly belong to the 21st century. I want Euro Safety Group to be a pioneer of such in India; and hence see this as an integral element of our broader strategy.

TCM: Elaborate on the challenges of marketing operations in India vs. overseas, after when you started in 2015?

Varun: The Indian market is very different from the export market of the developed countries. We are more price-conscious whereas they are quality conscious. Under my guidance, Euro Safety tried to provide PPE at Indian price points; without compromising one bit on quality, even if it meant having razor-thin margins.

At Eurosafety group we combine top quality raw materials, with international standards of safety and the latest European design elements – all at affordable rates.

On the flip side, it is somewhat easier to establish distribution channels and partnerships with Indian industries, since this market is well known to us.

 We have also smoothly integrated the latest marketing approaches in our mix, using tactics like “social listening”. To find out about the market’s upcoming needs and having regular interactions with our customers on our social media pages. Hence it is no surprise that to this day,

Euro Safety is one of the few companies that consistently provide world-class PPE products to the Indian market, all at affordable rates.

TCM: What nature of customer base do you serve, tell us more about that?

Varun: Euro Safety caters to all industry verticals from pharmaceuticals, construction, Agriculture sector, railways et al. Our diverse range of safety equipment is carefully engineered and designed in our state of the art laboratory. To guarantee utmost safety whilst keeping in mind the performance requirements of hazardous jobs. Our customizations of products as per the needs of various industries include, metal-free shoes for airport ground staff. And extra comfortable shoes for the air hostesses, washable, lightweight shoes with toe caps; for the hotel F&B industry and see-through transparent helmets for construction workers.

Our long-term vision is to have such a big customer base so as to become a household name in PPE in India and Asia.

TCM: Explain, how does Euro Safety create value for users and emerging businesses?

Varun: According to the International Labour Organization, only 20% of the Indian labour force is covered under adequate Health and Safety laws, resulting in over 48000 fatalities yearly. I predict that very soon the Indian government will mandate safety guidelines in other industry verticals as well, more so because India is swiftly integrating with international trade pacts and protocols, which mandate certain minimum safety standards.

Understandably getting industrial and quality management certifications – for which world-class Personal Protective Equipment (PPE) is a prerequisite, is the new minimum benchmark for Indian companies if they want to remain competitive and obtain export licenses to developed countries.

Adequate safety standards at the workplace, simultaneously improve employee perception inside the company; and brand reputation outside, leading to both increased productivity and better sales. Under my guidance, Euro Safety Group is continuously helping Indian companies achieve these ends, all at Indian price points.

Also, with Prime Minster Modi’s “Make in India” initiative being implemented across many sectors. We foresee a spate of manufacturing activity in the coming 5 years, each requiring  lots of PPE. We at Euro Safety Group are prepared to meet this glut of demand and will support such initiatives throughout India.

TCM: How are you giving back to society, is Euro Group into CSR activities?

Varun: CSR is a relatively unpopular activity among most Indian mid-sized companies, but we choose to be different. The CSR initiatives of Euro Safety Group are undertaken by the Roger Foundation, where I am the founder and VP. It was on the 40th anniversary of Roger Group, that we decided it was the appropriate time to start giving back to society and starting our CSR arm. We believe in inclusive growth and thus try to make sure we do our fair share to help the underprivileged sections of society.

Roger Foundation tries to generate goodwill and growth in rural India. In sectors spanning rural development, women empowerment, healthcare and education.

TCM: What advice would you like to share with aspirants who would want to start their venture in the industry?

Varun: According to the PWC “World in 2050” report, the Indian economy is set to grow 10 times in the coming three decades. This incredible growth will require lots of new infrastructure projects, tons of manufacturing (and mining) and an overall improvement in our living and working standards.

Thus, this vertical of PPE manufacture is absolutely in phase with the changes India will go through; so as to emerge as a superpower economy and is only going to grow henceforth.

Also, I want to emphasize, that in this vertical, quality control is of paramount importance; since we cannot take chances with human life. Indian market holds great potential. With increasing regulations and awareness in India, I think it is only a matter of a time; when safety equipment won’t just be looked at as an unnecessary expense but more like imperative piece of work attire. I wish aspirant entrepreneurs well if they want to enter the PPE vertical and welcome their competition. After all, competition leads to better products at lesser price points, for the customers and I look forward to it.

TCM: Our sources tell us you have added a few new feathers to your cap – you won “India’s Greatest Leader” award and the Stars of the Industry “Best in Class” award, how do you feel about these?

Varun: Yes, I was recently awarded “India’s Greatest Leader” award by the URS Asia One magazine. And only last week,

I was given the Young Achiever award by Stars of the Industry in Mumbai.

I want to thank my whole team at Euro Safety for these achievements. It’s their hard work and dedication which made it possible. And I have reasons to believe that these awards are only the beginning of many. Such other milestones that we at ESFI will achieve collectively in future.

However, as a Director with a long-term vision for one of India’s most promising companies. I feel the biggest award that I and my team at Euro Safety can get; is when we become absolutely synonymous with all types of PPE in India. Thereby also becoming the prime reason for ensuring safety and saving lives of workers all over.

TCM: How many brands of yours are currently operational in India, as earlier you mentioned you started with only Euro Security?

Varun: Indian customers are not so much brand conscious, as they are price conscious – against this gradient, Eurosafety is constantly striving to increase its brand visibility and recall.

We sell our products under a variety of brands and labels – Euro Security is our premium brand offering head to toe safety products. We sell shoes especially customized for the Aviation and Hospitality market under the ‘Avio’ label. ‘Eurock’ is our budget safety footwear product, aimed at the masses. And finally, we sell a range of stylish industrial safety footwear and accessories, under the Canvas Club brand.

Most of the PPE in India is still made by the unorganised sector, who deliver unbranded products – Eurosafety wants to change that

in the next few years.

TCM: What is your vision for the company? And where do you see Euro Safety in the next five years?

Varun: From where I stand, in 5 years, Euro Safety Group is going to be the primary choice; of anyone’s need for protection and safety. Since we started marketing our products domestically, we have had an annual growth rate of over 500%. And we are making all the efforts to keep this figure going.

In 10 years from now, I wish to see Euro Safety Group as India’s leading PPE provider. An Indian MNC synonymous with PPE in the Indian and SE Asian market.

Varun summarises, The Indian economy is set to grow 10 times in the coming 3 decades. This incredible growth will require lots of new infrastructure projects; tons of manufacturing (and mining) and an overall improvement in our living and working standards.

In the coming years Euro Safety Group wants to meet; the demand of PPE in India’s head on and help Indian companies; embrace the future, where our workers will work under high degree of safety standards.”

]]> 0
Aveya IVF: Pioneering Artificial Intelligence Technology in Infertility Treatments Fri, 29 May 2020 10:42:13 +0000 Aveya IVF: Pioneering Artificial Intelligence Technology in Infertility Treatments Hampering the lives of millions of couples across the globe, infertility has been one of the major concerns, and to treat this problem, Aveya IVF has pioneered through technologically advanced techniques and solutions efficiently. After gaining a national reputation as the fertility centre of last resort […]]]>

Aveya IVF: Pioneering Artificial Intelligence Technology in Infertility Treatments

Hampering the lives of millions of couples across the globe, infertility has been one of the major concerns, and to treat this problem, Aveya IVF has pioneered through technologically advanced techniques and solutions efficiently.

Aveya IVF

After gaining a national reputation as the fertility centre of last resort over the years, Aveya has not merely covered the aspect of physical needs and conditions but also the emotional & spiritual requirements that are required in a fertility journey. Under the capable leadership of Dr Sahil Gupta, Aveya strives to build India’s most technological advance chain of IVF clinics. ‘We are using artificial intelligence and machine learning in addition to traditional methods of IVF to give a superior and predictable form of IVF treatment to our patients’


Dr.Sahil Gupta, Founder, Aveya IVF is a Harvard Business School Alumni, an industry expert and serial entrepreneur. At the age of 28, he started Aveya Fertility, a disruptive network of affordable IVF centres in India, bringing hope to thousands of families. Building on his success, he is on a personal mission to develop high quality, affordable reproductive care in India.

The CEO Magazine, in conversation with the Founder Dr Sahil, got the chance to know more about the infusion of advanced technology and AI in the company, his personal growth, plans, changing trends and more;

How did ‘IVF’ industry happen for you, what was your rationale behind your career move?

IVF is traditionally considered a treatment for the rich. Infertility in the low strata of the society is used a taboo to exploit couples socially. During my days at Safdarjung Hospital, I realised that having a baby should be a right available to everybody, regardless of their financial status. This drove me to do research and find ways to make fertility treatment more available to the masses.

What kind of hurdles did you face while you picked this as a career or later?

Infertility is a booming industry as fertility rates are constantly rising in the country. Adding technology, whether its computer vision or machine learning or robotics, always gets a push back from the industry since infertility treatments haven’t changed since decades. So, driving change and automating parts of the procedure was a significant hurdle in implementation as technology is usually not well accepted by doctors. 

What have you individually added to the organization/industry – of significance?

As the founder CEO of Aveya fertility, I believe we introduced the concept of affordable IVF in India.

On the technology side, At Aveya, we have used data from thousands of patients to develop a unique algorithm for ovarian stimulation protocol. This means that our patients have a scientific and predictable method of taking hormones as against the current hit-and-trial methods used in fertility clinics. At Aveya, our algorithm will tell you statistically accurate odds and save you money by offering alternate forms of treatment like egg donation and surrogacy if your odds are low. This is absolutely unique to the IVF industry in India.

We are investing in developing technology that will put us ahead of the curve in the long term. Our doctors and embryologist have been working tirelessly since the past 4 years to collect every small piece of data available in every cycle of IVF. Live birth rates in IVF process are statistically 35% and there is huge scope of improvement considering variations of success rates in different clinics and labs.

The kind of job you do, do you ever feet the performance pressure in providing client satisfaction? 

I love the challenge of being the CEO of this great organisation. We are at the forefront of innovation in terms of investing in technology and want to be the chain with the highest success rates all across the world.

Of course, a key part of learning is to fail and learn. We have multiple instances where some of our strategies fail but our collective knowledge and experience helps us get out of tough situations.

We are absolutely focused on customer satisfaction, we maybe building a company for profit but due to the nature of the industry, we have to be very empathetic to our clients. We hired psychologists to sit with our clients and provide support.

How is your relationship with your team, if you were your employee, would you be happy working for you?

The core management team at Aveya is like a group of friends. We are never shy of giving positive feedback and push each other to improve. If I were an employee, I would love to be part of such a team where there is so much potential to learn in a competitive yet relaxed environment. Infact, we take pride in leading the technology advancements in infertility in India. We invest in education, engineers and technology and collaborate with top scientists of the world to stay ahead of the curve.

Is there anything innovative that you introduced to the organization during your tenure of service?

Aveya has been a pioneer in using Artificial intelligence for Improving odds of IVF success.In the last couple of years, Artificial intelligence is making baby steps to increase the success rates of IVF treatment.

A majority of the success of an IVF process depends on the role of an embryologist. There has been no technology enhancements for these trained technicians in the past decade which assist them in standardizing the process. Therefore, there is a huge variability that can be seen in different labs. An ideal way to solve this problem would be to completely automate this process and reduce the manual variability that is seen today. That would completely change the game in the IVF industry and make IVF a consistently successful procedure. 

As a fast growing company in fertility space in India and the goal to be India’s biggest fertility chain, we are aware that we need to be front runners in developing and using technology and artificial intelligence tools. We believe we are on the right path and given the huge sets of unique data that are collecting along the way, we may end up with a major breakthrough in the fertility industry that has a global game changing impact.

Do you believe that a major chunk of our population is yet alien to the idea of IVF?

I wouldn’t deny that a vast chunk of the population is alien to the idea of IVF but it is rapidy changing because of the internet, social media and some popular Bollywood movie. It is so rapid, I would except the landscape to change within the next couple of years.

What core values have you maintained over your time of work that has kept you strong?

I think being honest with your team and the customer has been the core value at Aveya specially in the industry where there is so much distrust and so much uncertainty. I think the patients love the fact that we are truthful and transparent about their treatment and chance, no matter how uncomfortable that is.

]]> 0
MAKO MEDICAL LABORATORIES, COVID19 TESTING LAB ON TRACK TO BECOME MARKET LEADER Thu, 23 Apr 2020 11:45:31 +0000 Mako Medical LaboratoriesBest Laboratory service provider of the Year 2020 MAKO MEDICAL LABORATORIES, COVID19 TESTING LAB ON TRACK TO BECOME MARKET LEADER Mako Medical serves as an industry leader in how laboratories should truly support patients and healthcare professionals. Clinical laboratories are a critical component of health care. Approximately 80% of physicians’ diagnoses are a result of […]]]> Mako Medical Laboratories

Best Laboratory service provider of the Year 2020


Mako Medical serves as an industry leader in how laboratories should truly support patients and healthcare professionals.

Clinical laboratories are a critical component of health care. Approximately 80% of physicians’ diagnoses are a result of laboratory tests, according to Kalorama Information, a healthcare market research firm. Common routine tests include cholesterol level tests, HIV tests, pap tests, pregnancy tests, and substance abuse tests. Clinical lab testing is also used to monitor diseases and drug treatments. Specialty testing, which is often more costly, may include genetics, immunology, oncology, endocrinology, and other segments. The clinical laboratory market is highly competitive with hundreds of providers.

One of the pioneers in this space, Mako Medical thrives as a leader in the US market. With its nationwide presence, the company rests at a unique position for its uncompromised adherence to the best standards of quality; dedication to innovation and technology to change the laboratory and pharmacy industry.

The Mako Medical Laboratories was established in 2014, headquartered in Raleigh, North Carolina. Growing significantly with a multi-disciplinary approach, ithas quickly become one of the most desired laboratories and a perfect diagnostic partner for businesses, physicians, urgent care facilities, and many hospitals around the United States.

Mako Medical Laboratories has recruited the top Ph.Ds., chemists, and scientists to provide industry-leading innovation. It has developed many custom and proprietary tests and uses robotics/automation to improve precision and accuracy.


Mako Medical’s niche is service. Because they focus on every detail the team has built a service model that is flexible, customized, and efficient. Technology aids in the delivery of these custom services. The team develops its custom and proprietary methodologies and assays. Mako Medical Laboratories’ methods and assays are validated for reproducibility, precision, and accuracy. They utilize industry-leading next-generation sequencers that have the perfect combination of accuracy and high-throughput sequencing. It uses next level RT-PCR systems for targeted discovery genetic markers.

Mako Medical Laboratories utilizes robotics within each of its laboratory facilities. Once the testing is completed, the data is transferred on a simple and easy to read the customized report. This data is available online or through the Laboratory Information Management System (LIMS) or via the app.

The aim ofincepting Mako Medical was to initiate a company that would create a unique competitor in an industry that lacked options while using the resources to make an impact in the communities they serve. The entire team is focused on volunteering, helping with local nonprofits, giving back, donating, hiring military veterans, and supporting many charities.

The team focuses on every aspect of the patient experience. This helps them develop processes that are unique and allows them to compete. They also leverage emerging technologies to disrupt how services are delivered and consumed.


Mako Medical Laboratories’ work begins within the brick and mortar of its facilities but its impact reaches beyond the laboratory doors and settles into the community.The company’s exclusive and even expanding service portfolio holds groundbreaking solutions that are clinically proven effective in curing the preventing diseases.

  • Award-winning laboratory services with patented technology
  • Next-Generation Sequencing for Clinical Trials and Research
  • Over 1300 different blood tests offered using the latest in robotic technology and automation
  • Customized result reports that are easy to read and understand
  • Fastest Turnaround Times in the industry
  • Access to results on your mobile device

Mako Medical Laboratories’ services are merely a vehicle to change lives locally and globally through healthcare advancement and resource allocation.


  • MAKO’s clinical pathology laboratory utilizes state of the art analyzers that require less blood then most chain laboratories, making MAKO’s testing more patients friendly.
  • It provides customers with the choice of over 1300 individual tests.
  • MAKO gives you access to the experienced and highly trained laboratory scientists to answer questions about results and other testing questions.
  • The company delivers customized result reports for easy to read summaries to providers resulting in clearer clinical interpretation and more concise clinical information.
  • This lab has heavily invested in state-of-the-art instrumentation and technology. It utilizes industry leading next-generation sequencers and next-level RT-PCR systems for targeted discovery of genetic markers.
  • Mako Medical Laboratories can process over 3100 different clinical laboratory tests.  The custom reporting, in-house logistics team, and focus on every detail has created a world-class patient experience.
  • The company is widely-known for its competitive pricing and is in-network with every major insurance company.
  • Mako Medical Laboratories’ facilities are equipped with state of the art robotics to ensure accuracy and precision with each sample. Also, each laboratory is outfitted with the industries leading LC-MS/MS, chemistry analyzer, and enzyme immunoassay technology.


The biggest challenges are the unpredictability of healthcare. No one knows what’s coming next. It is always evolving and new technology is changing the way they interact with patients and customers. Staying ahead of these changes is vital.

The focus is to expand into rural markets that lack access to quality healthcare. The team at MAKO is committed to long term care and helping the aging population with new care models and better access within their home.


Mako has built a loyal customer base because they actively engage them in the process. They get feedback and constantly adjust of the process to meet the specific needs of customers.Flexibility, service, technology, and building a program built exclusively on the feedback of customers have helped the firm a lot in the progress.

The firm has built strategic partnerships with healthcare providers and has leveraged customer feedback to access new customers. Organic growth through the exhausting markets.


The Mako Medical Laboratories team is led by scientists and doctors who specialize in methodology development and pathological services. There is a highly trained team of medicalengineers, who custom methodologies for the specific needs of patients. This process gives Mako Medical’s customers a distinct advantage when searching for specialized care and individualized medicine.

The management team at the companystrive hard to create an excellent work environment that recruits and attracts top talent. They have an entire team focused on building programs that enhance culture and make Mako Medical a great place to work. They have always been focused on “why” they do what they do and not the “what”. Innovation is the key here. Developing and designing new ways customers can consume the service both through Mako Medical and MakoRx. This will be their focus as they expand into new markets.


Mako Medical has experienced rapid growth and has won many awards in this category. They set a record as the only company ever to win the Fast 50 #1 three years in a row. They also placed 284 on Inc. Magazine’s Inc. 500 list. Mako Medical has also won awards for quality, community service, and innovations in healthcare.

Watching all the good work Mako Medical has done by supporting local nonprofits, charities, and hiring military veterans has been fuel for the team and the growth. The team stays motivated because as a group they focus on the why not the what. They are all passionate about helping others—this is what motivates themevery day.


Mako Medical Laboratories is passionate about making an impact in people’s lives.  It spends thousands of hours volunteering with local nonprofits and has donated medical services to those that don’t have access.  Mako currently supports over 472 local nonprofits and charities (military service dogs, homes for the blind, disabled, special needs children, horses for those that are paralyzed, veterans, cancer research, etc.).

Mako Medical Laboratories supports children with disabilities, veterans, cancer research, and faith-based ministries. Moreover, the company employs only military veterans for many of its positions, and supports over 80 Christian missionaries around the world.

]]> 0
VASCULAR CONCEPTS, ONE OF THE MOST TRUSTED BRANDS FOR STRUCTURAL HEART DISEASE DEVICES Fri, 20 Dec 2019 06:24:32 +0000 VASCULAR CONCEPTSVASCULAR CONCEPTS, ONE OF THE MOST TRUSTED BRANDS FOR STRUCTURAL HEART DISEASE DEVICES Living in a world of growing pressures contributing to a risk of hypertension, increased cholesterol levels, excessive smoking and a hassled lifestyle that eventually leads to innumerable cardiovascular diseases, the need for technological advancement has amplified with time. Addressing these risks of […]]]> VASCULAR CONCEPTS


Living in a world of growing pressures contributing to a risk of hypertension, increased cholesterol levels, excessive smoking and a hassled lifestyle that eventually leads to innumerable cardiovascular diseases, the need for technological advancement has amplified with time.

Addressing these risks of effectively, Vascular Concepts Limited, under the wise guidance of Swaminathan Jayaraman-CEO, is providing affordable solutions with an aim to develop technology that largely addresses the root problem with their wide range of products comprising of Balloons for Coronary Artery Diseases, Rheumatic heart diseases and Stents to treat Coronary artery disease and peripheral artery diseases.

The firm sits proudly at an enviable position in the medical device ecosystem, where they offer a complete variety of products for structural heart disease which includes Closure Devices (ASD, PDA, VSD, PFO) with an entire kit of accessories, covered stent for endovascular treatment of co-arctation of aorta, percutaneous Aortic Valve which to treat aortic valve disorders in patients through a minimally invasive approach.

The CEO Magazine grabbed a chance to connect with the team at Vascular Concepts and got to know their perspective on the industry, future, technological advancements, corporate ethos and more;

TCM: Do you believe yourself to be the most trusted medical device company and why?

Vascular Concepts: We prefer calling ourselves as ‘one of the most trusted brands’. We have a long-standing existence in the market with results at par, and at times even better than our multinational counterparts. We are in the healthcare industry for more than two decades now, and our purpose is to provide a superior quality cardiac implantable product at an affordable cost, along with results that add value to the money spent. We host a broad range of stents and other cardiac closure devices, as is the need of the industry. Outdated products keep getting removed or upgraded.

TCM: How do you reach to your end-user, what difference do you provide?

Vascular Concepts: We reach to our end users through their health care providers i.e. the cardiologists. We provide telephonic follow up and counselling with due consent of the doctor; offer them stent insurance in case of reoccurrence of blockage at the same site. We use different techniques of reaching out, and patient awareness programs for welfare and post-procedure care. We bring international experts to train and guide our doctors, we are not just sellers, but partners to our cardiologists, where we bring them reliable and high-quality products for use, keep them informed, and participate in national and international conferences.

TCM: Do you feel the technology and market have transformed over the years?

Vascular Concepts: Yes, doctors have gained access to global information, research, outcomes and impacts. They can now view international live cases or attend seminars from the comfort of their own country. Earlier they would have to wait for attending major international conferences to know the updates. They now train themselves successfully using the latest software & share their success stories with their peers all over the world. With our doctors connected to the western world, they now have access and availability of expertise equally in our country. Hence, the medical device industry grows unilaterally across the globe and the cardiologists are more capable of sharing their learning experience as well as opinions with their mentors or seniors. Also, AiMED currently is organizing the medical device companies and is spearheading the representations that are necessary for policy-making playing a key role in creating a voice for all.

TCM: In a competitive market, what hurdles did you have to battle?

Vascular Concepts: We as an Indian company, procure our raw material internationally from one of the best vendors of the market in Europe. Assembling and packing are done locally at our factory in Bangalore. Still, we sell at significantly lesser costs than other multinationals. However, our Indian competitors have been able to offer at much lower prices. Price War has always been a challenge. A basic minimum cost has to be maintained upon with increasing costs in research & improvement, and fighting competition in this arena was and still is tough.

TCM: How do you chalk out a business model for a successful medical firm?

Vascular Concepts: A successful medical device firm needs to continuously innovate and find disease segments that are either not treated or undertreated. There are several such market opportunities available for the medical device industry. The development of devices for these markets should undergo vigorous testing and should withstand long term success. If a company can do this successfully with the least amount of capital deployed it can then offer the products at competitive pricing to the patients.

TCM: What natures of clients are you associated with, and is there status satisfaction?

Vascular Concepts: We are currently associated with Interventional Cardiologists who do minimally invasive procedures to treat heart blockages or close coronary ducts. We are already enjoying the status satisfaction, as I had previously mentioned about a very comprehensive product array. We are also looking at adding new and upcoming devices, so I am confident that we shall not just maintain the status but also create an identity of a continuously innovative company. This is across several disease segments related to cardiac function.

TCM: Do you believe this is an appropriate time for one to step foot into the industry?

Vascular Concepts: Not really. There is a lot of turbulence in the industry at the moment, similar and varied quality of products have mushroomed, the price war has gone way beyond comprehension and its difficult to maintain exceptional quality quotient at such compromised costs. Research and innovation, which is mandatory for maintaining the quality of the product, are almost impossible to keep up with, at such falling costs.

TCM: What are the achievements and awards earned by you?

Vascular Concepts: We offer the patient an innovative range of medical implantable products to improve their quality of life. We are the recipient of the “2017 Asia-Pacific Coronary Care-Drug Eluting Stent Growth Excellence Leadership Award” presented by the business consulting firm, Frost & Sullivan. Before this, Vascular Concepts has also received the prestigious Alexandria-Frost & Sullivan Award for Excellence in India Healthcare, under the ‘ Indian Medical Devices Company of the Year ‘ in 2010 & 2011.

TCM: What role does ‘Make in India’ play for your industry?

Vascular Concepts: Make in India encourages manufacturers to step into the industry and bring to our citizens, reasonable products and meet the medical needs of patients, as we understand our country’s diseases and symptoms much better than multinationals. Imported products are mostly made as per the western needs and then dumped on the Indian prototype, due to lesser options being made available for us. ‘Make in India’ can only be successfully implemented by sincere market research and quality product development.

TCM: What core values and compliances are followed by you to maintain the value across the industry?

Vascular Concepts: We are clear in our vision to not get bogged down to low-cost demands because we do not compromise on quality. Research/PMS is performed in-house and is an ongoing practice since we have been in the market. It helps us keep a close eye on our product performance and quality. Our other core value is innovation, which has been the backbone of us relentlessly upgrading our existing products. Compliance for us is a part of our day to day activity and every employee is attuned to keep this value at the forefront. Rules and regulations are taken seriously and deviations/malpractices are not accepted and feel competition should be healthy and products provided must not be compromised in quality, due importance should be given to both, cost and quality.

Vascular Concepts are a pioneer in initiating a unique patient welfare program promoting health & wellbeing of patients implanted with stents. It is called the ‘Heart Insure Program’, a one of a kind service in India, which aims at disease management post angioplasty & takes care of the financial burden to undergo a repeat procedure. The patient is covered under special insurance & does not have to pay any premium. If the patient surfaces restenosis at the site of stenting, the company covers up the cost for the second procedure with a free device.

]]> 0
Zuvius Lifesciences, Revolutionising Health with Affordable and Unique Oncology Solutions Thu, 19 Dec 2019 06:47:00 +0000 Nimish Thakkar, Zuvius LifeSciencesZuvius Lifesciences, Revolutionising Health with Affordable and Unique Oncology Solutions Imagine a world free of cancer, a place where everyone is healthy and happy. Imagine a world filled with a golden glow of wellness. Striving to create a perfect world such as this is Zuvius Lifesciences Zuvius Lifescience Pvt. Ltd. is a research-based Pharmaceutical Company […]]]> Nimish Thakkar, Zuvius LifeSciences

Zuvius Lifesciences, Revolutionising Health with Affordable and Unique Oncology Solutions

Imagine a world free of cancer, a place where everyone is healthy and happy. Imagine a world filled with a golden glow of wellness. Striving to create a perfect world such as this is Zuvius Lifesciences

Zuvius Lifescience Pvt. Ltd. is a research-based Pharmaceutical Company manufacturing chemotherapeutic formulations of international quality standards, offering a diverse array of innovative solutions and therapies.

With a vast portfolio of more than 130+ oncology products, Zuvius the leading company in oncological products provides support and solution to patients battling cancer. Headquartered in Mumbai, India, Zuvius was initiated as an initiative to comfort cancer patients through quality treatment. The team of professionals at Zuvius have directed their efforts to develop simple and precise early diagnosis methods for cancer and to make quality treatments available and accessible to patients across the world.

Since inception, the brand has always strived to retain its tag of being an innovative company. Under the leadership of the founding team of Zuvius, Nimish Thakkar, Alka Chavan, Shailesh Shetty and Dr Ulhas Ganu, Zuvius has overcome several hurdles in this journey to becoming a leading developer of high-quality super speciality chemotherapeutic products.

From the MD’s Desk

“Welcome to the world of Zuvius Lifesciences !!!

We, at Zuvius, specialize in chemotherapeutic formulations, offering a diverse array of innovative solutions and therapies, each of which plays an important role in providing solace and comfort to the people. The Zuvius corporate culture is characterized by its ability to adapt quickly to our customer needs and requirements.

Our team unity is the key growth factor that has helped us to reach such great heights.

“Know Cancer to No Cancer” is our message to the society. The battle against cancer is a collective effort. Spreading awareness is one of the major activity Zuvius would get involved in coming years.  Promoting early diagnosis, and helping people overcome the fear of cancer would really help people to combat cancer in a better way.  With our formulations, we want to make good health a celebration, everywhere.

Zuvius bring our traditional family values of ethics, honesty and trust to bear on modern and innovative ways of working and developing our business and associated relationships.

A clear strategic focus on niche oncology and nutraceutical segments, state-of-the-art infrastructure, value-based collaborations, partnerships and our policy-driven, goal-oriented approach constitute the key elements of our future growth model,” shared Nimish

Keeping Up with Trends

Zuvius Lifescience has been keeping up with the changes in the industry. It makes sure to be abreast with the latest trends not only domestically, but also at the global platform. With the same vision, the experts at Zuvius attend international conferences and industry events regularly, to have a bigger and better view of the industry.

The brand also has a dedicated team of experts who are focused on forecasting market trends and formulating innovative solutions. Being actively invested with dedicated efforts in research and technology of oncology is the key to the brand’s strategy of keeping itself at par with the tides of time.

Overcoming the Hurdles

Zuvius Lifesciences believes that the Indian Pharmaceutical Industry is one of the most developed and fastest-growing markets in the global scenario. India, the pharmacy of the world, produces about 20 % of the world’s drugs. However, the nation still has some obstacles to overcome.

The first and most pressing challenge in the industry today is of access and availability of affordable drugs in the remote interiors of the country. The brand is ready to aid the government in building high-facility hospitals in rural areas.  Zuvius team believes that it would drastically change the statistics of cancer diseases in the country. The country has medicines but lacks the proper resources to ensure that the medicines reach the ones in need. Zuvius aims to overcome the challenge with its broad range of anticancer drugs and strongly believes that ‘the disease doesn’t differentiate between rich & poor and so shouldn’t care.’

Difficulty in exporting medicines to countries with high demand is the second hurdle the brand has to hop through in the industry. With so many rules and regulations from both the countries, especially for the pharma sector, exporting often becomes expensive and complex. The brand believes that the challenge is addressed by the Indian Government as it is working very hard to appraise the Indian pharma standards. Extensive efforts are taken so that medicines can be easily supplied seamlessly across the globe, thereby opening new doors of possibility for the pharmaceutical industry.

Proper research and development is the third and most important challenge. Over the years, the companies have accepted and created a dire need for better research component. Though the Indian Pharma Industry is growing at a rapid pace, the profits generated are not enough to support the expensive costs of research, as compared to its counterparts in other countries such as the US. Zuvius believes that India needs friendly government policies that would encourage research and studies in the field of pharma.

Having mentioned the government’s role that is required to transform the industry, the most essential part is the government’s reforms. Regulatory reforms in India and abroad tend to be different, creating a need for the Indian government to pace up.

Regulatory Reforms in India and Abroad

After coming a long way in terms of development, India is yet to walk a long road. The nation is in need of better regulatory reforms to promote drug research and development. Compared to the economically developed countries that have academic researchers, India too has a large number of such experts. These experts are indeed keen on working on cancer research, creating a dire need for strengthening the academia-industry interaction supported by the Government.

The brand believes that there is an urgency to introduce reforms to ease the difficulties in conducting domestic clinical trials along with better solutions to tackle trial approval delays.

Beating the Competition

Keeping the brand on edge, competition is the biggest motivating factor for any organisation to grow and be inspired. Competition is a well of contemporary wisdom and it stirs Zuvius to strive harder. The spirited race keeps the brand informed and alert of the latest trends and tides. Viewing competition in this light, Zuvius believes competition helps relevancy to come automatically without much conscious effort.

Meeting the Standards

We at Zuvius Lifesciences, strive to provide our customers with quality products that exceed their expectations. We achieve this through our Quality Assurance program which is developed to ensure continuous validation and improvement in all areas of the manufacturing process.

The depth of experience, capabilities, knowledge of our technical professionals and advanced scientific analytical instruments ensures that a world-class quality of final products reaches our customers.

Our Technical Director, Dr Ulhas Ganu, heads this department which follows current Good Laboratory Practices (cGLP), in total quality management. Achieving this standard is a step towards the systematic and documented work culture that we follow.

The analytical skills of our experienced and qualified Quality Assurance and Quality Control team are supported by Sophisticated Analytical Instruments. Stringent in-process, quality checks are conducted at each entry and exit level of raw material and the packing material. Regular Validation of facilities, equipment, process, products & cleaning as per respective standard operating procedures are carried out at regular intervals. Other activities include Complaint Handling, Storage of quality record and control samples, conducting and maintaining Stability Studies, and preparation of Registration Documents (DMF) in accordance with the respective FDA regulations.

Advancing Via Technology

Advancement of technology has transformed the business approach over the years and has become a key differentiator for companies. Be it in terms of research and manufacturing or selling and procuring, technology has facilitated every spectrum of the business chain. It has helped brands to leverage opportunities as it has simplified things.

“From customer-centric technology relating to the health care providers, to manufacturing and R&D-focused technologies that can help enhance productivity and compliance, one can see visible benefits of technology in the areas of secured collaborative research, Quality by Design (QBD), Product lifecycle management (PLM), Modelling and simulation in process development analytics and visualizations,” quoted Nimish

Core Values

Zuvius corporate practices and commitment to enhance the cancer patient’s quality of life is defined by its core values. Ethical practices, ensuring quality, and delivering customer satisfaction are the core values that drive the Zuvius Lifesciences team’s actions. These values practised over an epoch of decades have established the brand as one of the most trusted names in the healthcare industry.

Employees and Ethos

Zuvius believes in a culture of symbiosis, or mutual benefit. We work together to maintain goodwill and an amiable atmosphere. This not only helps personal and professional relations but also strengthens and improves the business and production process.

Zuvius believes that employees are the soul of a company. It is their hard work and dedication that can bring a brick and mortar building to life. Thus, Zuvius makes sure to hold its team of professional employees with high regards and bind them with a bond of opportunity, appreciation and work satisfaction. The brand has always encouraged its employees to grow as the brand grows.

“Our yardstick of success brings the glow of health on everyone’s face”

We are as honest as our actions. Our core values define our corporate practices and demonstrate our commitment to improving patients lives. We have developed our core values from our experiences. Our past has taught us to never give up.

Delivering Quality with Research

Zuvius promises international standards of quality in every product from its diversified portfolio of more than 130 high-quality oncology products. Zuvius has ensured that every product is backed by extensive research and tests guaranteeing unmatched quality. Adhered to internationally recognized pharmaceutical standards, the formulations are created with the latest technologies and are well accepted across the globe including  Europe.

Zuvius is a research-based pharmaceutical company; hence, research and development are an integral part of the organization. Supervised by the hawk-eyed expert and one of the most eminent research scientists, Dr Ulhas Ganu, the team ensures to achieve unparallel qualitative success. With 27 years of experience in basic cancer research at TATA Research Centre and an innate grasp of the complex concepts of the super-speciality segment, especially Oncology, Dr Ganu is the prodigy of Pharmaceutical Management. The seasoned leader’s astute guidance and supervision lead the team to achieve the top position as he works in sync with the myriad problems encountered by a cancer patient and brings out the best solutions.

Witnessing the Transformation

Pharma industry has witnessed a tectonic transformation in the past decades. The presence of Indian Pharma companies in the international market has increased massively leading to increased Indian formulation and bulk drug exports.

“With research, safety and long-term efficiency of medicines being the prime focus, the industry over the years has adopted the technology. It has played a pivotal role in catapulting the pharmaceutical sector in terms of research, manufacture and reach. With so many brilliant minds of doctors, scientists and academics leading this industry, the transformations are sure for good,” said Nimish

He further added, “We also see a great change today in-patient care, which was hardly available earlier. Neutraceuticals is again the next segment which has seen a major turnaround with people getting more and more health-conscious.”

Milestones and Achievements

In its sprint of over two decades, Zuvius has blossomed as one of the forerunners in the oncology segment with specialization in world-class quality chemotherapeutic formulations. The brand has curated a portfolio of over 130+ anti-cancer drugs as a result of its constant endeavours to find solutions, crowning Zuvius as leading manufacturers of the widest range of anti-cancer drugs.

The unwavering efforts and undeterred will of the entire team in the pursuit of forming a cancer-free society have won Zuvius the recognition in the market and among the patients. The recent and the most valuable glories adorning the brand’s hat are the three consecutive National Awards and two International Awards.

Journey to Lead the World

“Reaching out to the people who need us the most, are the people who we need the most. In our mission against Cancer, we have the backing of a highly qualified professional team who understand every need. Here, some of the finest talents in the pharma industry bring together their cumulative expertise and experience. They also bring with themselves, the inherent visionary zeal to keep on trying harder, to keep on innovating. Their efforts will help people rediscover the joy of living life, without the shadow of despair”, shared Nimish

He further added, “The battle against cancer is a collective effort. People all over the world stand united in their crusade. To assist everyone, we want to reach out to the world. With our formulations, we want to make good health a celebration, everywhere. Already, we are making rapid strides on a level that’s global. So, in any dialect, Spanish, Mexican, Italian or Hindi.Zuvius Lifesciences will always stand for Redefining Health, Rediscovering Life.”

Steps towards the Mission

“Having served the industry since 1995, the brand is looking forward to the future full of hope and prosperity with the same zeal. With global trade opening the gates and new innovations marking the way, we believe the pharmaceutical industry holds potential to change the light in which health is viewed,” shared Nimish

He further shared “We are in sync with the mission we have set to achieve that is becoming a globally renowned and trusted brand as the right players drive the different branches of the company. We are in the process of building an ecosystem for the patients suffering from Cancer.”

Government’s Role

With the novel reforms by the government to uplift the bed of Pharmaceuticals and Life-science industry, Zuvius believes that there is scope for more powerful regulatory reforms that would strengthen the position of Indian Pharma in the global forum.

Government has already initated a Public Private Partnership model for building cancer healthcare centre across India, which will really bring a revolutionary change in the society.

“We expect better healthcare centres cropping up in the villages and remote areas where the health problems mostly go undetected for a lack of facility and finances. Internationally, the industry has a huge scope to expand in China, Japan, and American countries. Hence, reformed trade laws with these countries to levy the rules can help revolutionise the industry,” quoted Nimish

Insight into Future

Envisaging the future, a trait which every business tends to have is also driving Zuvius’s growth. Zuvius managing team has various ambitious goals for future including investment in innovation and research, the two core elements of change. The team is excited to work on many things in the pipeline, right from exploring the options in cancer cure to digging deep into the prevention, diagnosis, treatment and aftercare for cancer.

Early Diagnosis of Cancer and Biosimilars is a topic that the brand is aggressively working to build revolutionizing solutions. Expanding globally and reaching various countries with oncology solutions, is also an important aspect of the future that the brand focuses on which will help it spread the wings of light and hope.

Zuvius Lifesciences aims to be among the top five of the most trusted companies across the globe, recognized for its super speciality and anti-cancer products. The Company is driven by its vision to become a global leader in research and drug development in the field of speciality medicines. Driven by its vision, the company reinvents itself to achieve growth and leadership.

Supporting Cancer Fighters

Zuvius is extremely proud for creating the longest hand-printed ribbon of 6500sq ft. which is featured in Limca Book of record, 2018.

Zuvius team has been passionately involved in various programmes and takes an active part in understanding and curing the pains of the downtrodden, during their course of cancer treatment. Special Programmes like ‘Hope for Life’ and ‘Can Care’ have been created by the team to ensure assistance for cancer patients crippled with financial disability.

Associated with the Government hospitals, Can Care program is organized to help numerous poor and needy patients who cannot afford costly cancer treatments. The successful program has led to benefiting of more than 10000 patients.

The brand has been extending help to various NGOs under programmes like Cancer Free Village on the Move along with sponsoring and participating in various Cancer awareness programmes. Zuvius has been associated with Yuvraj Singh’s Foundation YouWeCan, Zuvius has visited around 28 universities across the country to educate more than 18000 students for cancer awareness.

“The day is not too far away when people will say, “Cancer? —we are not worried because Zuvius Lifesciences is here.”

]]> 0
Zim Laboratories Limited, Nagpur-Based Pharmaceutical Company Delivering Innovative Solutions with ‘OTF’ Technology Thu, 19 Dec 2019 06:42:13 +0000 Dr Anwar S. Daud, Zim Laboratories LimitedZim Laboratories Limited, Nagpur-Based Pharmaceutical Company Delivering Innovative Solutions with ‘OTF’ Technology Since its inception, the drug delivery solution providing company, Zim Laboratories has strived to penetrate newer areas of pharmaceutical technology and business. The pharmaceutical company was established in 1984, headquartered in central India, in the industrial belt of Nagpur. Zim Laboratories Limited serves […]]]> Dr Anwar S. Daud, Zim Laboratories Limited

Zim Laboratories Limited, Nagpur-Based Pharmaceutical Company Delivering Innovative Solutions with ‘OTF’ Technology

Since its inception, the drug delivery solution providing company, Zim Laboratories has strived to penetrate newer areas of pharmaceutical technology and business. The pharmaceutical company was established in 1984, headquartered in central India, in the industrial belt of Nagpur. Zim Laboratories Limited serves millions of its customers with its differentiated pharmaceutical products developed with proprietary technologies (modified release, taste masking and thin films).

Zim Laboratories is an EU-GMP, WHO-GMP Certified and ISO 9001:2008 accredited company supported by an excellent team of professionals and state-of-the-art facility. The company is engaged in the activities of research and development, manufacturing, distribution and marketing of oral solid dosage formulations and pre-formulations (PFI) covering tablets, capsules, dry syrups, pellets, intermediates, granules and orally disintegrating strips (ODS). Driving the company’s sustained progress is the need for constant innovation to deliver the unique drug delivery solutions resulting in niche products. The product range of business is divided into two segments, pre-formulation and finished formulations.

A pioneer in pelletization technology and expert of taste-masking technology, Zim Laboratories is constantly innovating and driving solutions with the latest technologies. It has recently developed Thinoral®, a patented technology platform to manufacture the Oral Thin Films (OTF) which is launched in India and emerging markets abroad. The brand is one of the few players in the industry who has mastered the OTF technology. The technology is patented with about 19 applied product/process patents for oral films globally.

Besides the OTF technology, the company also works with other technologies including modified release, solubility enhancement, stability enhancement and dosage form transformation. Zim Laboratories Limited is regularly audited and approved by the ministries of health of all the countries where they export the products including CDSCO in India.

Zim’s R&D Team

Dr Anwar S. Daud, the Managing Director at Zim Laboratories Limited has been leading ZIM’s R&D with the support of a professionally qualified team of more than 111 personnel. The R&D team includes a total of 5 doctorates, 81 post-graduates and 22 graduates.

Keeping Up with Industry Trends

Zim Laboratories Ltd. is one of the rare pharmaceutical companies which innovate on pharmaceutical formulation manufacturing processes. The strategy of the company is to create robust and versatile technology platforms which enable rapid development and manufacturing of high quality and at the same time affordable complex or differentiated pharmaceutical products which are focused towards patient convenience and treatment adherence.

Corporate Values for Zim Laboratories Limited

The ‘Zim Team’ ensures that the brand values are never compromised while working. With zeal to positively impact the lives of patients through compassion, excellence, in product quality, affordability and marketability empowered with innovation to enhance attributes of products and processes. The brand believes in strong partnerships which leads value enhancement for customers, mutual respect, trust and transparency as a part of its values.

Striving to deliver performance with teamwork, integrity and ensuring sustainability are also the core values of Zim Laboratories which leads the brand’s growth. Zim’s fast-dissolving OTF was awarded as the best innovation of a solid dosage form for the year 2016 by India pharmaceutical association.

Government’s Role in Pharmaceutical Market

“The government’s approach and push towards producing and marketing products domestically, the brands in India have legal enforcement of ‘genericization’ of off-patent drugs, and the emergence of e-commerce platforms for prescription drugs amongst after other disruptive changes in the ancient model of drug making. The paradigm shift in the market can be seen while it is moving towards an epoch where the patient holds the power to decide the drug he/she wants to take, rather than the prescriber & supply chain.” Dr. Anwar S. Daud shared his views on the current scenario of government’s role in the industry.

He further added “The credit for this massive revolution in the pharmaceutical business can also be conferred to the tightening of regulatory requirements with special emphasis on ethical marketing & data integrity and push towards affordability and convenience.”

The challenge that the government has provided in this situation are leading brands towards a competition promoting treatment adherence. Zim Laboratories are taking a lead to overcome the challenges by building high-quality, patient-centric & affordable medicines with extra advantages such as convenience in terms of taste, treatment frequency and so forth.

Technology that Empowers Solutions

ZIM uses its proprietary knowledge, technology and manufacturing process expertise to bridge the technology gap in Tier III Pharmerging and ROW markets while assisting local players in various geographies to launch differentiated / combination generic products to compete in their respective local markets.

Future Plans

A core of every healthcare company’s business model is Research and Development. The brand is planning to add a separate R&D centre for regulated market. Zim Laboratories Limited is directing its efforts towards supporting their PFI and finished formulation customers with a range of nutraceutical products. It is also planning to widen its market by using an e-commerce platform for marketing the same along with OTC products. The brand is also planning to get US FDA accreditation for its manufacturing facility.

Corporate Social Responsibility

Starting up in Nagpur, the brand always believed in ‘giving back’ to the society and community they are trading or doing business in. With such business ethics, the brand put efforts to uplift the local community by hiring the local Pharmaceutical and Scientific talent whenever possible and giving them a chance to achieve success at the highest level. It provides employment opportunity to around 1,200 youth in and around Kalmeshwar, Nagpur and believes that even as it expands globally, it will keep strengthening the roots and bettering prospects in the region.

Each year, the brand takes initiatives to foster a better tomorrow by making it a point to look at the health challenges faced by the country at large and its community in particular. While last year, the focus was on ‘visual impairment and blindness’, one of the major health hurdles faced by India.

MD Dr. Anwar S. Daud shared about the CSR activities the brand has been conducting from past several years. “Studies suggest that close to 80% of blindness in India is because of cataract and uncorrected refractive errors which are easily preventable if detected early on. We observed that financial constraints and lack of awareness often lead to eye health being ignored or left undetected until it becomes too late. This was leading to school dropouts as eye disease hampered classroom participation and learning.”

He further added, “In the Eye Health drive held over the last year, we covered 48 schools and conducted checkups for 7699 students. We have distributed 1614 spectacles free of cost for those suffering from refractive illnesses, treated 915 students suffering from watery eyes, burning or redness of the eyes and referred 110 children to hospitals for advanced eye treatment.”

Zim laboratories Limited has not only addressed the issue but has also managed to drum up awareness amongst the community about the importance of eye health and the need for regular health checkups. As they chose to conduct checkups for the student community, the sensitized students have started referring their parents and immediate family members and encouraging them to participate in eye checkups and seek treatment.

Besides this, the brand has also been helping villagers in creating small water reservoirs as an initiative to save rainwater, being it the only chance at having enough water to meet the demands. ZIM Laboratories Limited has also been coming forward to help nearby villagers who were facing challenging circumstances due to water shortage.

Building a ‘Sustainable’ Brand

Zim Laboratories Limited’s’ avid attempt to provide for the community along with nature by trying to convert dried water stream into a small reservoir for preserving water during rainy season showcases that the brand believes in “sustainability” concept while carrying on business activities. The brand has been an ideal example of how building a business empire is not only focused on trading but also delivering to the community.

]]> 0
TAS MED: CRAFTING INNOVATIVE PHARMA SOLUTIONS THROUGH NEW AGE TECHNOLOGY KEEPING ETHICS AT PAR Thu, 19 Dec 2019 06:34:37 +0000 Tas MedTAS MED: CRAFTING INNOVATIVE PHARMA SOLUTIONS THROUGH NEW AGE TECHNOLOGY KEEPING ETHICS AT PAR High-quality care for all, the present and future generations, the leading pharmaceutical company, Tas Med has been engineering innovative solutions to transform the lives of many suffering with life-threatening diseases. Over the years, technological innovations and science have developed various solutions […]]]> Tas Med


High-quality care for all, the present and future generations, the leading pharmaceutical company, Tas Med has been engineering innovative solutions to transform the lives of many suffering with life-threatening diseases. Over the years, technological innovations and science have developed various solutions and medicines to treat the diseases; the brand has been serving thousands of its clients with the new-age effective products in the Cardiac, Diabetic, Neuro, Gastro, Psychiatry, Ortho & General category.

For more than two decades, Tas Med (India) Pvt. Ltd. has been engaged in manufacturing and trading its exclusive range of products including Cardioprotective Medicine, Oral Hypoglycemic Medicine, Neuropsychiatry Medicine, Nerve Protective Medicine, Anti Epileptic Medicine, Orthocare Medicine, Gastro etc.

With a prominent foundation laid in the year 1993 at Chandigarh, a prominent north Indian city with rich medical care, the brand has been keeping its pace in the highly competitive market. Tas Med is having its associated 2 manufacturing units which are GMP certified & Schedule M complied manufacturing unit delivering quality products with precise composition, high effectiveness, long shelf life and no side effects.

Meeting the Challenges

While at present the challenges in the Indian Pharma Industry include government regulations, price control and cut-throat competition, the brand tends to not to take the load and create solutions that provide maximum satisfaction to their clients backed with the assistance of the visionary leader Gagneet Singh.

Changing Trends

Keeping up with the rapidly changing trends in the industry, the brand has been constantly updating its systems to be covered for any unforeseen situation that the future may present including the government regulations in the pharmaceutical and life science industry. It also updates the product line to secure its position in the game.

The Current Regulatory Reforms Scenario in Pharma Industry

“Regulatory Reforms, an act to ensure improved quality, reduce administrative burden and ensure better accountability, the government, however, must regulate the industry at par with international standards in a regular time frame. Being an eminent part of the industry we believe that sufficient time should be given to the pharmaceutical companies to comply with the changes.” CEO Gagneet Singh shares his views on the current regulatory reforms scenario in India.

Technology: Remodelling Medicine

The brand has adopted technology automation and its benefits to uproot the brand. Along with overall savings in time and labour, the Pharma industry has adopted technology and reduced human intervention where it was feasible which has helped in achieving operational excellence and economies of scale. The brand believes that maintaining higher standards of production quality along with cost-effectiveness has been boosted with the technology.

Transformation in the Industry

“Being a part of the economy, it is an obvious trait of the industry to consistently evolve and transform, however, do we believe that the transformation has been for the good or not? Well, the answer is Yes. The unethical FDCs without any rationale have been banned leading to benefit the patients. The vital therapeutic areas including anti-cancer have been introduced with the price control offering patients with cost-effective therapy. Many regulations such as identifying prescription drugs from packing, stability data for good quality of products, strict manufacturing norms have transformed the industry for good.” shares Gagneet Singh

Competition, Essential for Success

While beating the competition keeps a brand on the edge, a healthy competition allows the brand to remain relevant and motivated in the cut-throat market scenario. Under the leadership of Gagneet Singh, the team strives to achieve high standards while working passionately as Gagneet shares “It motivates us to keep our heads down and focus on achieving operational excellence.”

Promising Excellence

Being a part of the company, the brand assures quality control checks at every point with well equipped micro testing labs performed Quality Assurance (QA) and Quality Control (QC) professionals who ensure that the brand is delivering high quality based products to the employees.

Corporate Ethos TasMedians Follow

“Business Ethics are crucial and intrinsic to our business. As a prominent brand in the industry, we ensure that our employees and corporate partners are always in sync with the corporate ethos we have. Hence, we organize a program named “Accelerate” twice a year to reinforce our ethical culture. Every ‘Tasmedian’ is committed towards its Allies and customers. This drives everyone every day,” shares Gagneet Singh

Core Values

The brand has been maintaining the brand value in the market being sync with its values as a company, including:

  • Strong commitment to allies and customers.
  • Honesty and integrity and fair and transparent conduct
  • Supplying superior quality products.

Achieving the Success and Position It Seeks

“Being a part of the industry since 1993, we have achieved a certain status in the market while we aim to secure the position in the top 100 pharmaceutical companies in the next 4 years by adding new product lines and strengthening our marketing activities. We are heavily investing to add new products to keep up the pace and scale it up faster than ever before in the coming years. We believe to move faster rather than die slowly.” shares Gagneet Singh

Government: A Major Player in Industry Transformation

Government is playing an important role in redefining the industry by bringing in new regulations to ensure patient compliance. However, the brand believes that the changes must be brought in phases to ensure 100% compliance within the stipulated time frame.

An Insight into Future Planning

Being one of the fastest-growing pharmaceutical companies, the brand is planning to launch licensed products and nutraceuticals in various therapeutic segments it already operates in. With its advanced scientific and technical know-how, Tas med is strengthening its novel segments Gastro and Orthopedic with nutraceuticals/health supplements. It further believes that corporate hospitals will have a major role in shaping the industry in tier1 and metro cities. Tas med is continuing to improve the lives through collaborating with various health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

]]> 0
HiMedia Laboratories, Crafting Excellence with the Hi-tech Microbiology Media Labs Thu, 19 Dec 2019 06:20:13 +0000 Himedia LaboratoriesHiMedia Laboratories, Crafting Excellence with the Hi-tech Microbiology Media Labs Dr G. M. Warke, the visionary defined his brainchild HiMedia Labs as a brand “By the Scientists, For the Scientists, and Of the Scientists”, as he laid the foundation in 1976. The microbiology media manufacturing company, HiMedia Labs are one of India’s prominent laboratories contributing […]]]> Himedia Laboratories

HiMedia Laboratories, Crafting Excellence with the Hi-tech Microbiology Media Labs

Dr G. M. Warke, the visionary defined his brainchild HiMedia Labs as a brand “By the Scientists, For the Scientists, and Of the Scientists”, as he laid the foundation in 1976. The microbiology media manufacturing company, HiMedia Labs are one of India’s prominent laboratories contributing to the Pharmaceutical and Life Sciences industry. Since its inception, the employees and the highly qualified technocrats in top management are delivering solutions being in sync with the core value of the company i.e. ‘World Class Products at Affordable Prices’.

Dr Vishal G. Warke, Director of R&D- Cell Culture Biology, Immunology & Higronics divisions and his wife, Dr Priti Warke, Director of Regulatory Affairs, and Cell Culture Biology took over the brand’s Animal Cell Culture division in 2003 after they returned from the United States and continued the journey that initiated 44 years ago, paving the way for further success.

“The brand has been ‘leading from the front’ when it comes to delivering solutions with HiMedia’s Animal Cell Culture Division. We offer high-quality products including Stem Cells, Cell Lines, Primary Cells, Media for Biosimilars, Multi Compendial Chemicals, Assay Kits, Reagents and Laboratory Equipment, Sera for Cell Culture, Cell Culture Systems with it latest venture of development of media for manufacturing biosimilars,” Dr. Vishal G. Warke shared the solutions HiMedia Labs is offering in the industry.

Over the Years

Over the last four decades, the company witnessed the paradigm shift in Pharma and Bio-Pharma industries where small molecule manufacturing companies diversified into large Bio-Pharma manufacturing companies. Today, the brands in the industry manufacture therapeutic protein-based biomolecules like Insulin, EPO erythropoietin, growth factors (GMCSF, GCSF, etc.), and Biosimilars or magic bullets, namely, monoclonal antibodies (mAbs).

Meeting the Indian BioPharma Industry Challenges

With production volumes dictated by heavy Capex costs as well as high COGS, the Indian Biopharmaceutical industry faces the biggest challenge of providing high quality & affordable medicines to patients in need of the expensive therapeutic proteins.

In addition to manufacturing, marketing of newly available Biosimilars that have recently gone or are likely to go off-patent shortly is also a challenge within the industry. HiMedia as a brand is assisting in rapidly taking these molecules to the market by helping Biopharma manufacturers with the bioprocess development as well as optimized clone specific media development.

The brand provides media and bioprocess optimization to Indian companies so that they upsurge and produce large volumes of biosimilars from existing small bioreactors economically, thereby anticipating in playing a key role in the transition.

Working towards Innovation

The HiMedia team is a set of experienced and knowledgeable scientists who ensure being updated with the online official literature resources such as PubMed, Google Scholar, Research gate, various patent sites, etc. With Research and Development being the foundation of HiMedia, the brand invests its profits heavily (over 40%) in R&D especially in Animal Cell Culture division to meet the needs of Biopharma processes and media development. The organization has a State-of-Art, Upstream Media development and Bioprocess optimization lab, which is one of its kinds in India.

Recognitions and Awards

HiMedia Labs have never sought status and has remained focused on serving the scientific fraternity along with people of the nation and is being recognised for following the same approach. In 2019, Dr G. M. Warke was honoured as “Brand Ambassador of Maharashtra” in the category of research and innovation by Maharashtra Industrial and Economic Development Association (MIEDA), whereas, HiMedia was ranked as “Best Company of the Year 2018” in “Pride of Maharashtra” award series.

The brand has been felicitated as a first ranking unit from Nashik, Dindori Taluka for ‘Make-in-Maharashtra’ and ‘Make-in-India’ in the Maharashtra Investment Seminar 2016, by Honourable CM, Shri Phadanvis. HiMedia also received prestigious Rajiv Gandhi National Quality Award by Bureau of Indian Standards, India for quality services to the consumer in 2011 and Rajiv Gandhi National Quality Award Bureau of Indian Standards, India in 2006.

Ensuring Best Quality Products

HiMedia is certified with ISO9001:2015, ISO13485:2016, WHO-GMP, NABL accredited quality control lab as per ISO17025:2017 quality management systems. The brand assures the quality benchmarks including ISO guidelines, pharmacopoeia standards and other current regional guidelines with its stringent quality systems. The brand uses SAP, HANA and metadata analytics as a part of PAT (Process Analytical Technology) to implement QbD (Quality by Design). HiMedia Labs quality products are exported to Japan, USA, EU and many other countries.

Extending the Success

The Animal Cell Culture Division has set up a world-class upstream media development and bioprocess optimization lab as the Biosimilars sector is set to boom at a CAGR of 30-35%. Setting up an advanced Analytical Characterization Lab for mAbs and other therapeutic proteins, manufacturing media for Biotherapeutic protein production in their world-class cGMP facilities, in very large volumes, with single lot sizes of 5000 Kg are listed in the future endeavours of HiMedia. Additionally, they are working on developing media for storage and transportation of organs as well as a broad range of products to support the Stem Cell and Gene Therapy Industry. The brand will be a part of one of the largest in India and top media manufacturers in the world.

Government Spending and Industry Growth

“The Indian Government has been actively addressing and solving problems of the industry. However, there is a good scope to increase funding for Industry-Academia collaborations to translate basic scientific research into applied technology, thereby allowing brands to sell those products in the global market.” Dr Vishal G. Warke shares his views on the government’s role in the industry.

He further adds, “The government has extended support to start-ups via incubators; it can also support the companies which have crossed the SME segment with incentives, soft loans, grant in aid, subsidized land for projects etc., while we could help the govt. create an ecosystem that will support MSMEs in the Indian Biotech sector.”

Corporate Social Responsibility

With an aim to achieve a better and affordable lifestyle for fellow human beings, HiMedia contributes to the society with various CSR activities including the sponsoring the renovation of an entire food technology lab in Mumbai’s Institute of Chemical Technology, setting the Regenerative Medicine Research Centre as a joint venture with Sir J. J Hospital, Mumbai and an Autism Intervention Centre (AIC) namely, Paediatric Neuro Development Centre at Sion Hospital, Mumbai.

The organization has also donated a fully functional State-of-the-Art ‘Skin Regeneration Laboratory’ along with training modules, to the National Burns Centre, Mumbai. It works towards raising the level of education among underprivileged children by supporting Ishavidya’s endeavour.

Leading India to Global Platforms

“HiMedia is the lonely Pole Star in the Biotech Suppliers Space with respect to being the only Indian origin company amongst the “Top 10 Multinational Companies” in this segment. It is now time for Indian Biotech companies to rise and become global giants, rather than MNCs acquiring us. With this goal, we relentlessly march ahead to put our nation at the forefront in the field of Biotech, globally.” Dr Vishal G. Warke shares his views on how the Biotech Companies in India can lead the nation’s growth and position on global platform.

]]> 0
EASYMEDICO, THE FINEST OMNICHANNEL RETAIL&WHOLESALEPLATFORM FOR HEALTHCARE SERVICES Thu, 19 Dec 2019 05:34:14 +0000 Easy MedicoEASYMEDICO, THE FINEST OMNI CHANNEL RETAIL & WHOLESALEPLATFORM FOR HEALTHCARE SERVICES EasyMedico today has aced the consumer behaviour and the rapidly revamping modifications of it as well. The provision of making pharmaceuticals available at ease through the wholesale and franchise platform with retailers raising orders online through the virtual POS (Point of Sale) system directly […]]]> Easy Medico


EasyMedico today has aced the consumer behaviour and the rapidly revamping modifications of it as well. The provision of making pharmaceuticals available at ease through the wholesale and franchise platform with retailers raising orders online through the virtual POS (Point of Sale) system directly like the consumer using the e-commerce interface has proved as a boon for the consumer in the healthcare scenario. They understand the needs of a consumer, franchise partner and also the pain of a traditional retailer who has been pushed to the wall due to heavy discounts offered by online players. EasyMedico is able to help everyone with a one-stop-solution for high-quality medical care and supplies at an affordable cost.

In the coexisting scenario with the brick and mortar players are companies rooting for the best healthcare services and ease to be provided to the consumer in need, online and offline both. An omni channel retail & wholesale platform of this nature for one of the best healthcare services in India is EasyMedico.

Today, EasyMedico, run by Suresh Naagar, Co-Founder & CEO, is changing the lives of medical pharmacies in a big way by disrupting the way supply chain was being looked at. Under his wise supervision, the company has created an ecosystem where they consider retailers as key partner.Right from taking care of the pain these retailer go through while dealing with 10-15 different stockiest for daily purchase to also ensuring that they can now buy more for the same amount at a single window.

Suresh added, “We ensure that with the use of EasyMedico retailer POS they don’t have to make numerous calls to discuss margin and then place an order over phone resulting in human error and loss of opportunity. And not just that, now there is no more a need to store multiple invoices of different stockists for years and years to do an expiry settlement. *EasyMedico is a complete one-stop solution for everything*. We make life easy for our retailers.”


Suresh Naagar, Co-Founder & CEO, EasyMedico defines a strategy for the business and closely oversees its execution. Suresh is an MBA from the University of Chicago-Booth School of Business. He is a seasoned leader and management executive with over 20years of experience. He has successfully worked with fortune 500 companies playing different roles, and his prior entrepreneurial experience allows him to wear different hats under different circumstances with equal ease.


EasyMedico is an aggregator, retail supplier and Omnichannel pharmacy chain; they are tech-driven aggregator & single point supplier to Franchise and non-franchise medical stores (knows as EasyEnabled stores). They have a matured platform & their backend ecosystem empowers traditional medical stores and new entrepreneurs to run their stores most efficiently. They have 20 EasyMedico franchise stores across Madhya Pradesh, Ecommerce Portal (online), Whatsapp & Tele-calling and are the last mile fulfilment partner for pure on-line players, alongwith catering to 100+ non-franchise retail stores with the help of retailer POS deployed at stores.

“Even after 4yrs since inception, we continue to evolve our processes, we are not afraid to try new things and fail. Where we are today is all because of constantly researching and updating ourselves” states Suresh. 


There are several challenges, and with every challenge, there lies a potential opportunity like supply chains, customer experience, reach and costs are some of them. There is room for efficiency gain in each of these and hence they are focussing on – availability, accessibility, and affordability. They see technology as one of the biggest enablers in bringing in efficiency and at the same time, human touch allows them to have a direct feed from the stakeholders which further drives innovation. They look at each interaction point as a mutually rewarding long term relationship.

Technology has brought in significant benefits to the Pharma industry at multiple levels, right from manufacturing to the last-mile delivery to the consumer. Information flow has been much faster than ever and the domain that still requires help from the technology is primary care.


“The nature of zero tolerance around health, safety, and integrity drives every process at EasyMedico. We value quality more than the quantity, while quantity gives us scale in less time, quality rewards in the long run” asserts Suresh. 

We strictly follow all the guidelines for storage, dispensing and disposing of medicines. All the medicines are dispensed by a registered pharmacist and stored at a proper temperature conditions as storage conditions indirectly affects the efficacy of medicines

While the cost of medicine has always been the talking point, it has gained pace in recent years across the globe and India is not isolated from that. There is a greater awareness around generic substitutes,biosimilars and bioequivalents. With the cost of hospitalization, treatment is going up; this will continue to gain momentum with an increase in trust due to quality improvement and some endorsements by doctors.


The Pharma industry has certainly evolved, and from the supply chain side, there are visible disruptions, the company today is at the forefront of this change, though not in scale at this moment certainly, they have been ahead of times. Being a true omni channel pharmacy retail chain for a long time with a strong foothold, EasyMedico would aggressively grow retail supply through a new state of the art warehouse and finely engineered processes.

Suresh emphasizes, “The growing competition has not affected us much, as we are always able to find a synergy even in the competition. Our business model allows that flexibility. We are a fulfilment partner and last-mile supplier for anybody and everybody, irrespective of whether revenue comes through our direct customer or the competitors and online players.In a diverse market like India, there is a room for everyone to do well, at the same time those who would continue to grow without increasing the cost base significantly will stay around and get rewarded.”

EasyMedico feels that as long as their inventory is utilized and their partners are benefited, they will continue to handle the competition with an open mind. For them, there is always room for good organized retail brand, aggregator & supplier. EasyMedico solves countless issue of an existing retailer and feel that over some time consolidation may happen in online play as well as supply side of it. Today when everything shifting towards online, Suresh feels, “physical footprint will continue to remain relevant, many a time people do prefer personal touch and quick re-check on relevancy and schedule of prescribed medicines at a neighbourhood pharmacy store. Post doctor consultation or even without it, such kind of conversation gives them lot of comfort.”


At EasyMedico, employees are their assets;respect for an individual is primary whatever pressured situation it may be. In today’s environment, each member of the team has clarity on their goal and then there is a role that is constantly evolving. Technology helps identify the trend before it becomes an issue while human touch helps in looking at things from the customer’s point of view and come up with the most appropriate solution.

“Brand value is of prime importance to us when it comes to franchise operation; we have a standard format that is followed. We have not gone for masses, but for quality and customer experience, this is visible across all of our franchise stores. It is also true when we on board a non-franchise retailer as Easy Enabled store. They are required to follow laid down processes including use of EasyMedico supplied POS for raising order to ensure they are the main beneficiary at the end in terms of cost, quality and time” added Suresh. 


While the company started as pure e-commerce venture way back in 2015, looking at India as a market so very diverse, they were quick to understand the need to be an omni channel player and started opening EasyMedico branded physical stores along with continuing with eCommerce ops. They are the largest branded retail chain in central India and also the largest aggregator, supplier of multibrand medicines to traditional retail stores.

The company is looking forward to leading in central India as a single point supplier to the retailer and the largest branded retail chain. EasyMedico is changing the century old habit of retailers, while making them tech-savy, they are also asked to give up “credit”mind set (udhari, also called as site of few days), at the end of each day, EasyMedico has no recoveries / collection due from anyone – i.e. we don’t sell on credit.For the last 2 months, they have been growing at 30% in terms of revenue,& retailer on-boarding with EasyMedico POS is at near 50% growth, an additional revenue channel started in mid-July. These numbers would further get a boost with capacity enhancement through a launch of new 5000sqft warehouse in Indore.They are able to maintain good ~15% bounce rate, and quick turnaround time. This along with the inventory level & utilization will further improve with the insight from artificial intelligence & data analytics, something they are watching very closely.


“Our new warehouse of 5000sqft will be operational in Oct. We are growing non-franchise traditional retailers’ base by 50% month on month, with a current count of 100 retailers, we will be supplying to almost 500+ retailers in the next 3-4 months. We will also continue to expand our franchise footprint, aim is to open at least one franchise store in each ‘Tehsil’ of Madhya Pradesh. We are committed to growth while keeping the cost base low.” states the CEO. 

Growth in Franchise base will speedup as some conversion will happen from on-boarded traditional retailers into EasyMedico franchisee. There is a significant gain in becoming a part of the EasyMedico branded retail chain. Life is much easier for the franchise owner, it’s a different league altogether with tech driven touch & feel health & wellness store. Clearly they will continue to enhance their purchase margins with increase in volume. They will launch private label product sometime mid next year, by then the customer base, franchise base, and retailers count would have increased significantly, this network will help the brand promotion &product adoption much faster.

Suresh wraps with, “EasyMedico is largely funded through family and friends, and we expect to go out forfund raising sometime in Dec-Jan. This fund will be utilized for expanding our customer base, capacity expansion, launch of private label products, and technology enhancement.”


  • Rajesh Khuranais the COO and head of supply chain & procurement. At EasyMedico, he has been instrumental in introducing the Franchise model to build a 100 store strong chain in Central India. He brings with him, a rich experience of 30 years in the retail and consumer goods industry, having worked with reputed brands like Samsung, NEXT, HAIER, etc. He had earlier launched many retail brands and has been responsible for the rapid expansion and retail roll-out.
  • Ankit Alya is the co-founder and head of business development & marketing. He looks after franchise development and retention, sales, marketing, establishing generic substitution at the store level, launching own products and importantly expansion into district/tehsil level in MP. Ankit is a former Brand Manager of Sun Pharma’s best revenue-generating brands like Pantocid, Mesacol, Lactifiber is B.Pharm and MBA in pharmaceutical management from NarseeMonjee, Mumbai. Experienced in various domains of healthcare industry like strategic brand management, supply chain management, training of medical representatives, brand registrations for export business, the establishment of quality generics and Ayurvedic portfolio.
  • Vinay Chhajlaniis the Group Chairman, Founder, and Strategist behind group companies – Diaspark and Webdunia among others. He has also been Non-Executive Director at Network18 Media & Investments Limited and Info media Press Limited. He has an MS in printing technology from Rochester Institute of Technology, USA and a bachelor in engineering from BITSPilani. A seasoned entrepreneur and a tech start-up veteran, Vinay has built internet and technology companies since the dot com era and is a keen believer of value creation, and this is what he aspires EasyMedico to do as well.
  • Alok Bachhawatis an MSc in International Management from Royal Holloway, University of London. Coming from the formidable JBGroup, Kolkata – Alok heads the leasing and renting vertical, whilst also launching the business centres& interior designing verticals for the group. With EasyMedico, Alok further diversified his portfolio by venturing into retail & e-commerce business.
]]> 0
CONCORD BIOTECH LIMITED: THE BIOTECHNOLOGICAL POWERHOUSE, ENHANCING THE LIVES THROUGH ACTIVE PHARMACEUTICAL INGREDIENTS Tue, 17 Dec 2019 10:52:03 +0000 Concord Biotech LtdCONCORD BIOTECH LIMITED: THE BIOTECHNOLOGICAL POWERHOUSE, ENHANCING THE LIVES THROUGH ACTIVE PHARMACEUTICAL INGREDIENTS The triumphant rise of India’s pharmaceutical industry is characterised with consistent growth and being a leader in supplier of affordable drugs over the last three decades. As a result, the Indian pharmaceutical industry today stands as the third-largest globally in terms of […]]]> Concord Biotech Ltd


The triumphant rise of India’s pharmaceutical industry is characterised with consistent growth and being a leader in supplier of affordable drugs over the last three decades. As a result, the Indian pharmaceutical industry today stands as the third-largest globally in terms of volume. It is expected to become the world’s largest supplier of drugs by volume as well as one of the top five pharmaceutical markets globally by 2030. India is also the 3rd largest manufacturer of active pharmaceutical ingredient (API) in the Asia-Pacific region

One of the key segments in the Indian pharma industry is the biopharmaceutical industry, which contributes approximately US$4 billion. When it comes to Bio-pharmaceutical manufacturing companies in India, Concord Biotech Limited is a leading name. Concord is a vertically integrated, R&D driven biotechnological powerhouse that manufactures Active Pharmaceutical Ingredients, through fermentation and semi-synthetic process, and finished formulations. Founded in the year 2000, Concord Biotech has completely transformed from a single-product company to a broad-spectrum specialty drug provider, offering products across diversified therapeutic segments, including niche and complex therapies such as Immunosuppressant, Antibiotics, novel Antifungal and Oncology.

Concord offers a world-class API production infrastructure at Dholka, located near Ahmedabad, Gujarat, India which is spread across 114,000 sq. meters. It is a hub to the largest number of bioreactors in India with a fermentation capacity of more than 500 m3 and is in the process of constructing a new facility that will catapult Concord as the largest manufacturer of fermentation based small molecules. The manufacturing facility complies with cGMP and has been inspected by global regulatory agencies like U.S. Food & Drug Administration (USFDA), European Union Goods Manufacturing Practice (EUGMP), Japanese Accreditation of Foreign Manufacturers (AFM), and Korean Food & Drug Administration & State Goods Manufacturing Practice of India (GMP). Concord has commercialized APIs across high growth, specialty therapeutic segments like Immunosuppressant, Hematology, Oncology, Anti-fungal, Antibacterial and Anthelmintic (Animal health). Fermentation-based products had been a challenge to India and India was totally dependent on China but Concord became the first company to take this challenge and is now exporting the fermentation based products to various countries across the globe including China.

Concord also offers Contract Research & Manufacturing services of APIs in the area of fermentation & semi-synthetic molecules.  All in all, Concord is focused on becoming a strong player in Contract Research and Manufacturing of fermentation and semi-synthesis based Bio-pharmaceuticals through its expertise in…

  • Strain Improvement & Media Optimization
  • Fermentation/ Biotransformation process development
  • Down Stream & Semi-Synthetic/ Synthetic process development
  • Process scale-up & Optimization

In 2016, Concord forward integrated to finished formulations with a vision to supply globally including the regulated markets, focusing initially on solid orals, liquid orals & topical of Immunosuppressant products and then followed by a solid oral dosage of Oncology and specialty formulations.


Sudhir Vaid

Sudhir Vaid is the man behind the victorious journey of Concord Biotech. He is the Chairman and Managing Director of the company and holds over 40 years of extensive experience in the field of corporate R&D & consultancy with leading domestic & global API companies.

 Researcher turned entrepreneur, Sudhir has interest in Pharmaceutical Industries (Generic & Branded), Biotechnology, and Life Sciences (including Medical Devices). Since 2000, he has been instrumental in building Concord Biotech, from a start-up venture into one of India’s leading manufacturers of active pharmaceutical ingredients and formulations.

Ankur Vaid

Ankur Vaid is a big influence in developing the R&D division, contributing to the market strategy and at the same time, spearheading the entire organisation towards its goals and objectives. Ankur did his masters in Finance after completing his graduation in Chemical Engineering. Playing a vital role in the promoter group, he has performed tremendously across various business verticals and brought efficiencies thus providing a major boost to the growth of the company.


The founder of Concord Biotech, Sudhir Vaid considers Gujarat as his “Karma Bhumi”, and took over the multinational manufacturing unit in Dholka in 2000. Later, he transformed this chemical facility to Biotech facility by starting production of its first product Amidase Immobilized Enzyme. With his core strength in fermentation, Concord then diversified itself into fermentation-based niche API manufacturing from 2003.

Today, Concord has become one of the largest manufacturers of fermentation-based APIs in the world with more than 20 dedicated API manufacturing blocks having over 500 M3 fermentation capacities. As a part of the forward integration strategy, Concord has now ventured into Finished Dosage Form. A state-of-the-art formulation, development and manufacturing facility spread over 95000 Sq. meters at Valthera, located near Ahmedabad, India was commissioned in 2016 to manufacture pharmaceutical dosage forms like solid orals, oral liquid, and suspensions, complying with global regulatory norms and already accredited by the US-FDA The company has also initiated selling of finished dosage products in the USA.


The team of Concord Biotech combines expert professionals specializing in the field of pharmaceuticals. The team is a perfect blend of highly competent Biotechnologists, Biochemists, Chemists, and Engineers, Pharmacists and Management experts, who are continuously focusing on the development of high-value & low-volume Biotech APIs and complex Finished Dosage Forms.

Concord Biotech is globally recognized for its products and has a commanding presence in more than 50 countries worldwide and supplying to some of the leading MNC and Indian Pharma companies across North America, Europe, Japan, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries, besides significant presence in India.

 With respect to finished formulation, at present Concord Biotech is serving 1200+ Nephrologists, 250+ Transplant Physicians & 250+Immunologists/ Rheumatologists & 500+ Intensivists based at major Tertiary healthcare centres. Concord is  linked with more than 500+ Healthcare Centres with its  available product range and distribution network which involves 120+ Supply Chain Management Partners. The in-house products of the company are available in major Corporate Hospitals & Government Setups.

Here Road ahead:


Concord is an R&D based Biotechnology company having state-of-the-art Fermentation Facility. Here is the list of major driving force that makes this company stand out in the market:

  • Concord offers a fully integrated platform with a diversified portfolio of Active Pharmaceutical Ingredients and finished dosage products in the area of Statins, Immunosuppressant, Antibiotics, Anti-fungal, Oncology, Anti-Obesity, and others.
  • Concord has a strong track record of product development capabilities, with expertise in developing complex molecules with non-infringing processes
  • Concord has a quality driven approach with a regulatory market mindset and has been inspected by numerous global regulatory agencies like US-FDA, EU-GMP, Japanese AFM and local FDA.
  • It has the largest number of Bioreactors in India with total fermentation capacity>500m3 and additional capacity of >1200m3 which will be ready in the second quarter of 2020.
  • Concord’s 20 Dedicated API manufacturing blocks for the different class of products allows the company high flexibility in manufacturing at competitive cost
  • There is a competent and proficient team of scientists to handle various projects in defined targets/ timelines.
  • Having a presence in the global market and working with key global pharmaceutical and biotech giants in the world


Concord Biotech is creating strategies to expand its manufacturing capacities to support the increasing demand for its commercial and pipeline products. It has acquired 160 Acres of land in Gujarat and started the implementation of the state of the art world’s largest Biotechnology facility with respect to number of bioreactors. The facility will be ready in May – June 2020.   Concord is also on the way to expand its horizons by partnering with leading Global Pharmaceutical Companies by meeting their product development needs for API’s & Finished Formulations.

]]> 0